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Abstract X-linked adrenoleukodystrophy (X-ALD) is caused
by mutations in the ABCD1 gene encoding ALDP, an ATP-
binding-cassette (ABC) transporter located in the peroxisomal
membrane. ALDP deficiency results in impaired peroxisomal
β-oxidation and the subsequent accumulation of very long-
chain fatty acids (VLCFA; > C22:0) in plasma and tissues.
VLCFA are primarily derived from endogenous synthesis by
ELOVL1. Therefore inhibiting this enzyme might constitute a
feasible therapeutic approach. In this paper we demonstrate that
bezafibrate, a PPAR pan agonist used for the treatment of
patients with hyperlipidaemia reduces VLCFA levels in
X-ALD fibroblasts. Surprisingly, the VLCFA-lowering effect
was independent of PPAR activation and not caused by the
increase in either mitochondrial or peroxisomal fatty acid
β-oxidation capacity. In fact, our results show that bezafibrate
reduces VLCFA synthesis by decreasing the synthesis of C26:0
through a direct inhibition of fatty acid elongation activity.
Taken together, our data indicate bezafibrate as a potential
pharmacotherapeutic treatment for X-ALD. A clinical trial is
currently ongoing to evaluate the effect in patients with X-ALD.
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Introduction
X-linked adrenoleukodystrophy (X-ALD: OMIM 300100)
is an inherited metabolic disorder characterized by im-
paired peroxisomal β-oxidation of very long-chain fatty
acids (VLCFA; ≥C22) and accumulation of VLCFA
(mainly ≥C26:0) in plasma and tissues of patients
(Moser et al 2001). It is caused by mutations in the
ABCD1 gene (http://www.x-ald.nl), encoding a peroxi-
somal transmembrane protein named ALD protein (ALDP:
OMIM 300371) (Mosser et al 1993). Clinically, X-ALD is
characterized by a striking and unpredictable variation in
phenotypic expression, ranging from the rapidly progressive
childhood cerebral form (CCALD) to the more slowly pro-
gressive adult form adrenomyeloneuropathy (AMN) and var-
iants without neurological involvement (“Addison-only”
phenotype) (Moser et al 2001).
Experimental pharmacotherapy in X-ALD was aimed at
normalizing VLCFA β-oxidation and VLCFA levels. Over
the years several compounds have been investigated, such
as Lorenzo’s oil (Aubourg et al 1993; van Geel et al 1999),
4-phenylbutyrate (Kemp et al 1998), and lovastatin
(Engelen et al 2010; Singh et al 1998). These treatments
were shown to be either unpractical or ineffective in clinical
trials and therefore other drugs are needed.
Fenofibrate (a PPAR-α agonist) was shown to induce
expression of ALDR (Abcd2) in the liver of Abcd1-/- mice
(Netik et al 1999). ALDRP is a functional homolog of
ALDP (Kemp et al 1998). However, fenofibrate has no
effect on Abcd2 expression in the brain of Abcd1-/- mice,
possibly because it is a substrate for the Mdr1 transporter at
the blood brain barrier and therefore does not penetrate
into the brain very effectively (Berger et al 1999). For
this reason, we investigated the effect of several other
drugs known to activate PPAR on VLCFA metabolism in
cultured skin fibroblasts from patients with X-ALD. The
results described in this paper show that bezafibrate (BF),
but not fenofibrate, clofibrate or other PPAR agonists,
could reduce VLCFA in cultured fibroblasts from patients
with X-ALD.
The VLCFA which accumulate in X-ALD, are partly
absorbed from the diet (Kishimoto et al 1980), but mostly
result from endogenous synthesis through elongation of
long-chain fatty acids (Tsuji et al 1981). Recently, we iden-
tified ELOVL1 as the key enzyme responsible for the syn-
thesis of VLCFA and demonstrated that knock-down of
ELOVL1 resulted in lower VLCFA synthesis and reduced
levels of VLCFA in cultured X-ALD fibroblasts (Ofman et
al 2010). Hence, inhibiting fatty acid elongation (for exam-
ple by inhibition of ELOVL1) by pharmacological means
could be a potential treatment for X-ALD. Here, we show
that BF lowers VLCFA in X-ALD fibroblasts by direct
inhibition of fatty acid elongation.
Materials and methods
Chemicals
Deuterium-labeled palmitate-16,16,16-D3 acid (D3C16:0)
was purchased from CDN isotopes (Pointe-Claire,
Canada). A 12.5 mM stock solution in dimethyl sulfoxide
(DMSO) was prepared. BF, fenofibrate and clofibrate,
WY14643, GW501516, and rosiglitazone were purchased
from Sigma-Aldrich (St. Louis, MO, USA). Stock solutions
in DMSO were made of 400 mM (BF and clofibrate),
50 mM (fenofibrate), 10 mM (WY14643 and rosiglitazone),
500 μM (GW501516). MK-886 was purchased from
Cayman Chemical (Ann Arbor, MI, USA) and a stock
solution of 50 mM in DMSO was used. Prior to usage the
stock solutions were vortex mixed and diluted in HAMF10
tissue culture medium to the final concentration. All chem-
icals used were of analytical grade.
Cell lines and cell culture
Primary human skin fibroblasts were obtained from X-ALD
patients through the Neurology Outpatient Clinic of the
Academic Medical Center. From each patient written in-
formed consent was obtained. X-ALD diagnosis was con-
firmed by VLCFA and ABCD1 mutation analysis. Control
fibroblasts were from male anonymous volunteers. Cells
from patients with a peroxisomal biogenesis disorder were
obtained from the laboratory cell bank. Cells were grown in
HAMF10 supplemented with 10% fetal calf serum, 2.5 mM
HEPES, 100 U/ml penicillin, 100 U/ml streptomycin and
2 mM glutamine. Cells were used between passage numbers
6 and 20. Culture media were refreshed every 5 days.
Fatty acid synthesis
Synthesis of D3-VLCFA in intact cells was measured using
D3-C16:0. Assays were performed in triplicate. Cells were
seeded at 40% confluency in T75 flasks. The next day,
medium was replaced by fresh medium supplemented with
D3-C16:0 (dissolved in DMSO) at a final concentration of
50 μM. After 72 hr, cells were harvested and VLCFA
analyzed as described (Valianpour et al 2003).
Measurement of fatty acid β-oxidation
Mitochondrial β-oxidation activity of intact fibroblasts was
measured by quantifying the production of 3H2O from
[9,10-3H(N)] oleic acid as described previously (Moon and
Rhead 1987). Peroxisomal β-oxidation activity of intact
fibroblasts was measured using [1-14C]-26:0 as described
previously (Wanders et al 1995). All measurements were
performed in triplicate for each cell line.
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Immunofluorescence and counting of peroxisomes
Fibroblasts where grown on glass microscopy slides in 6-well
plates with or without 400 μM BF. Cells were fixed with
paraformaldehyde and permeabilized with Triton X-100.
Peroxisomeswere visualized by catalase immunofluorescence
microscopy as described previously (Kemp et al 1996). To
count peroxisomes, we made images of immunofluorescence-
stained cells after focusing on the cell nucleus, and determined
the peroxisome number per cell with the aid of a colony
counter. For each cell line and condition, 10 cells were
counted at random.
Quantitative RT-PCR analysis
ELOVL1, ELOVL4, ELOVL6, ACOX1, ABCD3 and CPT1a
mRNA levels in control and X-ALD fibroblasts growing in
log phase were determined as described (Engelen et al
2008), with primer sets presented in Table S1 (Supporting
information Table S1).
Purification of mouse liver microsomes
Microsomes were isolated from livers from wild type and
transgenic ELOVL1 over-expressing mice (Kemp et al manu-
script in preparation) by differential centrifugation as described
by Baudhuin et al (Baudhuin et al 1964), with minor
modifications. Livers were washed with ice-cold homogeniza-
tion buffer containing 250 mM sucrose, 2 mM EDTA, 2 mM
DTT and 5 mM MOPS (pH 7.4), minced and homogenized
using a potter tissue grinder with Teflon pestle with 5 strokes at
500 rpm. A post-nuclear supernatant was produced by centri-
fugation at 600 g for 10min. The supernatant was centrifuged at
22,500 g for 10 min and the pellet was discarded. Next, the
supernatant was centrifuged for 1 h at 100,000 g to obtain a
microsomal fraction. The pellet was resuspended in homogeni-
zation buffer containing 10 mg/mL methyl-β-cyclodextrin and
sonicated for 4 times 5 seconds at 8Wwith a 1 minute interval.
Themicrosomal membranes were collected by centrifugation at
100,000 g for 1 h. Finally, the microsomes were resuspended in
homogenization buffer and stored at -80°C until further use. All
steps were carried out at 4°C. Protein concentrations were
determined using BCA as described (Smith et al 1985).
Fatty acid elongation assay
The fatty acid elongation assay was carried out using a method
adapted from Nagi et al (Nagi et al 1989). The reaction
mixture contained 50 mM potassium phosphate buffer (pH
6.5), 10 mg/mL α-cyclodextrin, 1 mM NADPH, 5 μM rote-
none, 60 μM [2-14C] malonyl-CoA (6.5 dpm/pmol)
(American Radiolabeled Chemicals, St Louis, MO) and
20 μM C16:0-CoA or 20 μM C22:0-CoA (Avanti Polar
Lipids, Alabaster, AL), in a total volume of 200 μL. The













































CFig. 1 Only BF, and not other
drugs from the fibrate class,
reduces C26:0 in X-ALD
fibroblasts. (a) C26:0 levels in 3
X-ALD cell lines cultured for
7 days without drugs (black
bar), in the presence of BF
(gray bar), fenofibrate (white
bar), or clofibrate (hatched bar).
(b) C26:0 levels in 3 X-ALD
cell lines cultured for 7 days
without drugs (black bar), in the
presence of BF (gray bar), ago-
nists of PPAR-α (WY 14643),
PPAR-β (GW 501516) and
PPAR-γ (rosiglitazon), or with
different combinations of PPAR
agonists (white bars). (c) C26:0
levels in 8 control (white bar)
and 8 X-ALD cell lines cultured
without (black bar) or with
400 μM BF (gray bars) for up
to 3 weeks. Fatty acid levels are
in nmol/mg protein. Data are
mean±SD. *0p<0.05,
**0P<0.01, ***0P<0.001 by
ANOVA followed by Dunnett's
multiple comparison test com-
pared with untreated X-ALD
cells
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reaction was started by adding 100 μg protein of the micro-
somal fraction and allowed to proceed for 30 min at 37°C.
NADPH dependency was tested by performing the reaction
without NADPH. Reactions were carried out with or without
BF or BF-CoA (100 – 400 μM). The reaction was stopped by
adding 200 μL 5 M KOH in 10% methanol, saponified at 65°
C for 1 h and acidified by adding 200 μL 5 NHCl and 200 μL
96% ethanol. Fatty acids were extracted three times with 1 mL
hexane and the hexane phases were collected in a scintillation
vial to which 10 mL scintillation cocktail (Ultima-Gold,
Perkin Elmer) was added and radioactivity counted.
Synthesis of bezafibroyl-CoA (BF-CoA)
BF-CoA was synthesized by a method adapted from
Rasmussen et al (Rasmussen et al 1990). Dichloromethane
(DCM) and tetrahydrofuran (THF) (Merck) were dried with
molecular sieve deperox (Fluka). Triethylamine and ethyl-
chloroformate (Merck) were diluted to 1 M with dry DCM.
The reaction contained 36μmol BF dissolved in 1.4 mLDCM/
THF (5:2) and 40 μL 1 M triethylamine. The reaction mixture
was incubated at room temperature for 10 min under constant
stirring and under an atmosphere of nitrogen. After 10 min, 40
μL 1 M ethylchloroformate was added and the incubation was
continued for 45 min. After the incubation, the mixture was
dried under nitrogen and dissolved in 0.5 mL tert-butanol.
Next, 40 μmol CoA trilithium salt (Sigma-Aldrich) dissolved
in 0.5 mL 0.4 M potassium bicarbonate was added and the
sample was incubated for 30 min at room temperature. The
reaction was stopped by adding 100 μL 0.1 N HCl. BF-CoA
was purified using a C18 solid phase extraction column
(JTBaker). The column was eluted by a gradient of acetonitrile
and 40 mM ammonium acetate, starting with 10% acetonitrile
and 90% 40 mM ammonium acetate increasing to 50% aceto-
nitrile and 50% 40 mM ammonium acetate. Acetonitrile was
evaporated and purity was checked by HPLC. BF-CoA was
quantified using 5,5’-dithiobis-(2-nitrobenzoic) acid (DTNB)
(Sigma-Aldrich). Themethod used was an adaptation of that of
Ellman (Ellman 1959). BF-CoA was diluted in 20 μM MES
buffer pH 6.0, an equal volume of 2 M NaOH was added and
the sample was incubated for 30 min at 50°C. The reaction was
neutralized with 2 M HCl. Absorbance at 412 nm was mea-
sured and the concentration was determined using a calibration
curve of CoA trilithium salt (Sigma-Aldrich).
Results
Effect of BF on endogenous VLCFA levels and de novo
C26:0 synthesis in fibroblasts from patients with X-ALD
We tested the effect of several drugs from the fibrate class, but
found that only BF reduces C26:0 levels, both fenofibrate and
clofibrate being ineffective (Fig. 1a). BF is a PPAR pan-
agonist activating all three PPARs. To determine whether the
effect of BF on C26:0 levels is mediated by activation of either
PPARα, PPARβ/δ or PPARγ, X-ALD fibroblasts were incu-
bated with the PPARα ligand WY14643, PPARβ/δ ligand
GW501516, or the PPARγ ligand rosiglitazone either alone or
in all possible combinations. Only treatment with BF reduced
C26:0 levels by about 30% after 7 days (Fig. 1b).
To examine if longer incubations with BF would result in
a further decrease of C26:0 levels, we cultured X-ALD
fibroblasts for up to 21 days. This resulted in a small
additional decrease of C26:0 of 10% after 14 days and
15% after 21 days, respectively (Fig. 1c). No signs of





























Fig. 2 BF, but not other fibrates, inhibits D3-C26:0 synthesis. (a) D3-
C26:0 synthesis from D3-C16:0 in 5 X-ALD cell lines cultured for
3 days without drugs (black bar) and in the presence of BF (gray bar),
fenofibrate (FF, white bar), or clofibrate (CF, hatched bar). (b) D3-
C26:0 analysis from D3-C16:0 in 4 control (white bar) and 4 X-ALD
cell lines cultured for 3 days without (black bar) or with increasing
concentrations of BF (gray bars). Fatty acid levels are in nmol/mg
protein. Data are mean±SD. **0P<0.01, ***0P<0.001 by ANOVA
followed by Dunnett's multiple comparison test compared with un-
treated X-ALD cells
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cytotoxicity or impaired growth as determined by the MTS
cell proliferation assay (CellTiter 96® Aqueous One
Solution Cell Proliferation Assay) were observed (data not
shown). Previously, we validated the use of stable-isotope
labeled fatty acids to study VLCFA de novo synthesis in
whole cells and demonstrated that the synthesis of D3-C26:0
from D3-C16:0 is elevated in X-ALD fibroblasts (Ofman et
al 2010). Earlier work has shown that BF is a potent inhib-
itor of long-chain fatty acid elongation, while clofibrate is
not (Sanchez et al 1993; Vazquez et al 1995). Therefore, we
tested the effect of BF, clofibrate and fenofibrate on C26:0
de novo synthesis. Of all fibrates tested, only BF affected the
de novo D3-C26:0 synthesis (Fig. 2a). BF reduced D3-C26:0
synthesis in a concentration-dependent manner. At 400 μM
BF, the synthesis of D3-C26:0 was reduced by 75% com-
pared with untreated X-ALD fibroblasts (Fig. 2b). At this
concentration, there was no difference in the amount of
newly synthesized D3-C26:0 between X-ALD and control
cells. We performed further experiments with BF, and not
the other fibrates or PPAR agonists, to identify by which
mechanism BF reduces C26:0 levels in fibroblasts from
patients with X-ALD.
The effect of BF on C26:0 levels is independent of induction
of mitochondrial or peroxisomal β-oxidation
BF and PPAR ligands in general are known to induce
mitochondrial and peroxisomal β-oxidation (Bonnefont et
al 2009; Cabrero et al 2001; Islinger et al 2007; Pyper et al
2010). The effect of BF treatment on the rate of mitochon-
drial and peroxisomal fatty acid β-oxidation was determined
in X-ALD fibroblasts. Exposure of X-ALD fibroblasts to BF
caused a 50% increase in C16:0 β-oxidation (Fig. 3a), and a
35% increase in C26:0 β-oxidation (Fig. 3b). Since it is
known that fibrates induce peroxisome proliferation in
rodents (Islinger et al 2007), we determined the amount of

















































CFig. 3 Effect of BF on
mitochondrial and peroxisomal
β-oxidation and peroxisome
number. Measurement of (a)
C16:0 β-oxidation and (b)
C26:0 β-oxidation activity in 5
control cell lines (white bar)
and 5 X-ALD cell lines cultured
without (black bar) or with
400 μM BF (gray bar) for
7 days. Activities are in pmol/
mg/hour. Data are mean±SD.
*0P<0.05 and ***0P<0.001
by ANOVA followed by Dun-
nett's multiple comparison test
compared with untreated X-
ALD cells. (c) Peroxisome
number in 10 X-ALD cell lines
cultured without (white bar) or
with 400 μM BF (gray bar) for
3 days. Mean and quartiles are























Fig. 4 C26:0 reduction by BF is not mediated by increased peroxi-
somal β-oxidation. Analysis of de novo D3-C26:0 synthesis in 3 X-
ALD (black bar) cell lines and 3 cell lines from patients with a
peroxisomal biogenesis disorder (PBD, white bar). Cells were incubated
with 50 μM D3-C16:0 for 3 days without or with 400 μM BF (cross-
hatched bars). Fatty acid levels are in nmol/mg protein. Data are mean±
SD. ***0p<0.001 by student’s unpaired t-test
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with BF. We did not find any evidence for an effect of BF
treatment on peroxisome abundance (Fig. 3c).
BF reduced C26:0 levels in cultured X-ALD fibroblasts,
while other drugs of the fibrate class or other synthetic
PPAR agonists could not. This strongly suggested that the
effect of BF on VLCFA levels is not dependent solely on
induction of mitochondrial or peroxisomal β-oxidation,
since the other compounds should have been effective as
well then (Blaauboer et al 1990; Kemp et al 2011). BF
treatment resulted in a 35% increase in the peroxisomal
C26:0 β-oxidation capacity (Fig. 3b). To test if the induc-
tion of peroxisomal β-oxidation by BF caused the reduction
in C26:0 levels, we incubated fibroblasts from patients with
a peroxisomal biogenesis disorder (PEX1, PEX6 and
PEX26) with BF and measured the effect on D3-C26:0 de
novo synthesis. The synthesis of D3-C26:0 from D3-C16:0
was reduced roughly 50% in peroxisome-deficient fibro-
blasts incubated with BF (Fig. 4). This clearly indicated that
the effect of BF on D3-C26:0 synthesis and C26:0 levels is
only partially mediated by an induction of the peroxisomal
β-oxidation capacity.
To investigate whether the induction of mitochondrial β-
oxidation by BF is responsible for the reduction in C26:0,
we used the PPARα inhibitor MK-886 (Kehrer et al 2001).
The induction of mitochondrial β-oxidation by BF in X-
ALD fibroblasts could be reversed with 50 μM MK-886,
suggesting that PPARα activation is completely blocked at
this concentration (Fig. 5a). Next, we measured D3-C26:0
de novo synthesis in X-ALD fibroblasts incubated with BF
in the presence of MK-886. Addition of MK-886 did not
affect the reduction of D3-C26:0 synthesis (Fig. 5b).
Combined, these data are highly suggestive that the reduc-
tion of C26:0 levels by BF is PPAR independent and can not
be explained by the increase in mitochondrial β-oxidation
capacity and only partially by the increase in peroxisomal β-
oxidation capacity. This suggests that BF inhibits the for-
mation of D3-C26:0.
BF directly inhibits fatty acid elongation
The amount of D3-C26:0 present is the net result of the
elongation of D3-C16:0 to D3-C26:0 by ELOVL6 and
ELOVL1, respectively (Ofman et al 2010) and the degrada-
tion of D3-C26:0 by peroxisomal β-oxidation. The inhibi-
tory effect of BF on the formation of D3-C26:0 could either
be indirect by affecting gene expression or direct by inhibition
of key enzymes involved in VLCFA de novo synthesis
(Ofman et al 2010). To investigate the effect of BF on gene
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Fig. 5 C26:0 reduction by BF is not mediated by increased mitochon-
drial β-oxidation. (a) C18:1 β-oxidation in 3 X-ALD cell lines cul-
tured without (black bar), or for 48 hours with 400 μM BF (gray bar),
or with BF and increasing concentrations of MK-886 (white bars).
Activities are in pmol/mg/hour. Data are mean±SD. (b) De novo D3-
C26:0 synthesis in 4 X-ALD cell lines incubated with 50 μMD3-C16:0
without (black bar) or with 400 μM BF (gray bar), 50 μM MK-886
(white bar), or 400 μM BF and 50 μM MK-886 (cross-hatched bar).
Fatty acid levels are in nmol/mg protein. Data are mean±SD. **0p<
0.01; ***0p<0.001 by ANOVA followed by Dunnett's multiple com-
parison test compared with untreated X-ALD cells
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*
Fig. 6 Effect of BF on gene expression of genes involved in fatty acid
metabolism. Expression levels of genes involved in fatty acid metab-
olism in 3 X-ALD cell lines cultured without (black bars) or with
400 μM BF (gray bars) for 48 hours were analyzed by quantitative
PCR. Data are mean±SD. *0p<0.05 by student’s unpaired t-test
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synthesis, peroxisomal β-oxidation and mitochondrial β-
oxidation we performed quantitative RT-PCR. As shown in
Fig. 6, there is only a small reduction in the mRNA levels of
ELOVL6, which is not statistically significant. There was no
increase in the expression of ACOX1. This is in line with
previously published data (Blaauboer et al 1990) and our
own data (Fig. 3c) showing that there is no peroxisome
proliferation, at least in cultured human cells, treated with
fibrates, in contrast to rodents (Blaauboer et al 1990). BF did
not induce the expression of ABCD3. Induction of this gene
was detected in mice treated with fenofibrate, and considered
to be the mechanism by which fibrates might be useful in
correcting the metabolic defect in X-ALD (Berger et al 1999;
Netik et al 1999). Our data show that induction of ABCD3 did
not occur in human X-ALD fibroblasts upon exposure to BF.
In line with previous data (Djouadi et al 2005), BF treatment
resulted in increased expression of CPT1a.
The previous experiments suggested that the effect of
BF on C26:0 levels and C26:0 synthesis could be me-
diated by a direct inhibiting effect on fatty acid elonga-
tion. VLCFA are synthesized by the concerted action of
ELOVL6 and ELOVL1 (Ofman et al 2010). ELOVL6
elongates C16:0 to C22:0 and ELOVL1 elongates C22:0
to C26:0. We measured the effect of free BF and BF
esterified to coenzyme CoA (BF-CoA) on C16:0-CoA
and C22:0-CoA elongation. In the elongation assay BF
had no effect. However, BF-CoA inhibited the chain
elongation activity of both C16:0 and C22:0 in a con-
centration dependent manner (Fig. 7). Both fenofibrate
and clofibrate did not inhibit C22:0-CoA elongation
(Fig. 7b). These data demonstrate that BF-CoA lowers
C26:0 levels by direct inhibition of fatty acid chain
elongation.
Discussion
Synthetic PPAR alpha ligands, like fibrates, are potentially
interesting compounds to investigate as therapeutic agents
in X-ALD because they are known to activate mitochondrial
and peroxisomal fatty acid β-oxidation (Vazquez et al
2001). They might therefore reduce VLCFA accumulation
by increasing VLCFA degradation. Indeed, Brown and col-
leagues demonstrated that treatment of two CCALD patients
with clofibrate resulted in a reduction in VLCFA (Brown et
al 1982). However, this reduction was not sustained. More
recent experiments showed that fenofibrate induced expres-
sion of both ALDRP (ABCD2) and PMP70 (ABCD3) in the
liver of Abcd1-deficient mice, but not in brain (Berger et al
1999). In Mdr1-/- knockout mice induction of ALDRP and
PMP70 in brain did occur, suggesting that fenofibrate is
indeed cleared from the brain by Mdr1 (Berger et al 1999).
These studies, however, did not report the effect on VLCFA
levels in tissues. In this paper, we studied the effect of
several classical fibrates and other synthetic PPAR ligands
in a cell model for X-ALD, and show that BF but not the
other fibrates reduced endogenous C26:0 levels. This C26:0
reducing effect could not be mimicked by other PPAR-
ligands which means that the effect is PPAR independent.
BF has been demonstrated to induce mitochondrial β-
oxidation (Bonnefont et al 2009; Djouadi et al 2005).
Blocking the induction of mitochondrial β-oxidation with
MK-886 did not prevent the reduction of D3-C26:0 de novo
synthesis in X-ALD fibroblast by BF. We also showed that
the peroxisomal C26:0 β-oxidation capacity in X-ALD skin
fibroblasts increased with 35% upon treatment with BF.
However this does not seem to be the only mechanism of
reduction of VLCFA in fibroblasts incubated with BF,









































Fig. 7 BF inhibits fatty acid
elongation. (a) Fatty acid
elongation activity of C16:0-
CoA (a substrate of ELOVL6)
in the presence of an increasing
concentration of BF (o) and BF-
CoA (●). (b) Fatty acid elonga-
tion activity of C22:0-CoA (a
substrate of ELOVL1) in the
presence of an increasing con-
centration of BF (o) and BF-
CoA (●) or with an increasing
concentration of fenofibrate
(FF, □) or clofibrate (CF, Δ).
Fatty acid elongation activity
was measured using 20 μM
C16:0-CoA or C22:0-CoA as
substrate with concentrations of
the inhibitor up to 400 μM.
Error bars represent the stan-
dard deviation
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because in cells from patients with a peroxisome biogenesis
disorder in which peroxisomal β-oxidation is completely
deficient, BF lowered D3-C26:0 levels as well. This strongly
suggested that BF might reduce C26:0 levels primarily by
inhibiting C26:0 synthesis. To test this we measured de novo
synthesis of D3-C26:0 from D3-C16:0 in X-ALD fibro-
blasts. BF indeed decreased de novo synthesis of D3-C26:0
in a concentration-dependent manner. At a concentration of
400 μM BF, D3-C26:0 levels in X-ALD fibroblasts were at
the level of control fibroblasts. The rate limiting enzymes
involved in synthesis of C26:0 from C16:0 are ELOVL6
(elongation of C16:0 to C22:0) and ELOVL1 (elongation of
C22:0 to C26:0) (Kemp and Wanders 2010; Ofman et al
2010). By qPCR we showed that expression levels of these
enzymes are not affected in fibroblasts incubated with BF
suggesting a direct inhibition of VLCFA synthesis.
Previously using rat liver microsomes other investigators
showed that BF inhibits palmitoyl-CoA (C16:0-CoA) elon-
gation in an in vitro assay (Sanchez et al 1993; Vazquez et al
1995). We used purified microsomes from wild type and
ELOVL1 over-expressing mice to test the effect of BF on
elongation of both long-chain fatty acids (LCFA) and
VLCFA. Our results demonstrate that BF-CoA, but not free
BF, is a potent inhibitor of both LCFA and VLCFA elonga-
tion. It should be noted, however, that these results do not
allow us to demonstrate at which level BF inhibits VLCFA
synthesis. Fatty acid elongation requires four sequential
reaction steps: (i) condensation between the fatty acyl-CoA
and malonyl-CoA to form 3-ketoacyl-CoA; (ii) reduction
using NADPH to form 3-hydroxyacyl-CoA; (iii) dehydra-
tion to trans-2-enoyl-CoA; and (iv) reduction to fully elon-
gated fatty acyl-CoA. The initial condensation reaction is
catalyzed by the enzyme referred to as “elongation of very
long-chain fatty acids” (ELOVL) and is considered to be
rate limiting (Cinti et al 1992). While seven elongases have
been identified in mammals (designated ELOVL1-
ELOVL7)(Jakobsson et al 2006), only a single enzyme has
been identified yet for the subsequent reaction step
(Jakobsson et al 2006). Identification of the specific en-
zyme(s) affected by BF is not a trivial thing and requires
detailed analysis of all enzymes involved, including: 3-
ketoacyl-CoA reductase (HSD17B12), 3-hydroxyacyl dehy-
dratase (HACD3) and the trans-2,3-enoyl-CoA reductase
(TECR). This will be the subject of future studies.
Concluding remarks
The work described in the paper shows that inhibition of
VLCFA synthesis by pharmacological means could be a
feasible treatment option for X-ALD. BF is a good candi-
date for this approach. BF lowers the levels of C26:0 by a
direct inhibition of the synthesis. Mouse studies to evaluate
the in vivo effect of BF treatment on VLCFA in X-ALD
mice would be interesting; however, the effect of fibrates is
quite different in rodents and humans. Watanabe et al dem-
onstrated that rats and mice are unusable as a model system
(for primates) to the study the effect of BF (Watanabe et al
1989). BF has a proven safety profile for (long-term) use in
humans. With a daily dose of 200 mg of BF peak plasma
levels of 50 μM can be reached, with a maximum daily dose
of 800 mg of BF therapeutic levels might be reached in
plasma (Miller and Spence 1998). A small scale proof of
principle clinical trial is currently ongoing to evaluate the
effect in X-ALD patients.
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